Regeneron Pharmaceuticals earnings were $4.5B for the trailing 12 months ending Jun 30, 2025, with 3.6% growth year over year. The latest REGN earnings report on Jun 30, 2025 announced Q2 2025 earnings of $1.4B, up 72.1% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, REGN reported annual earnings of $4.4B, with 11.6% growth.
REGN past earnings growth
How has REGN's earnings growth performed historically?
Regeneron Pharmaceuticals Earnings Reports & History FAQ
What were Regeneron Pharmaceuticals's earnings last quarter?
On REGN's earnings call on Invalid Date, Regeneron Pharmaceuticals (NASDAQ: REGN) reported Q2 2025 earnings per share (EPS) of $13.24, up 0.08% year over year. Total REGN earnings for the quarter were $1.39 billion. In the same quarter last year, Regeneron Pharmaceuticals's earnings per share (EPS) was $13.25.
Is Regeneron Pharmaceuticals profitable or losing money?
As of the last Regeneron Pharmaceuticals earnings report, Regeneron Pharmaceuticals is currently profitable. Regeneron Pharmaceuticals's net profit (also called net income) for the twelve months ending Jun 30, 2025 was $4.46 billion, a 3.17% increase year over year.
What was REGN's earnings growth in the past year?
As of Regeneron Pharmaceuticals's earnings date in Invalid Date, Regeneron Pharmaceuticals's earnings has grown 3.57% year over year. This is 27.99 percentage points lower than the US Biotechnology industry earnings growth rate of 31.56%. REGN earnings in the past year totalled $4.46 billion.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.